Business
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR
Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk of long COVID due to a longer treatment regimenPreparations are underway for FDA interactions and initiation of Phase 2 studiesData presentation to be provided at the Investor Event on March 31, 2025 at 10:00 AM ET NEWTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-sta
About this update from Traws Pharma, Inc.
[{"type":"image","alt":"Traws Pharma, Inc.","displaySize":"","headline":null,"caption":"Traws Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/b7f59076ee694ac5fc5d681bbcfa7af2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/O38eCot9fjUiIRrtl6lHyg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b7f59076ee694ac5fc5d681bbcfa7af2","width":300,"height":300}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk of long COVID due to a longer treatment regimen","length":191,"tagName":"p"}]},{"val":[{"type":"text","content":"Preparations are underway for FDA interactions and initiation of Phase 2 studies","length":80,"tagName":"p"}]},{"val":[{"type":"text","content":"Data presentation to be provided at the Investor Event on March 31, 2025 at 10:00 AM ET","length":87,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":358,"olType":false},{"type":"text","content":"NEWTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced that positive data supporting the potential for ratutrelvir, a main protease inhibitor, as a treatment for COVID-19, were presented on March 20, 2025 in a poster at the International Conference for Antiviral Research (ICAR 2025), held in Las Vegas, Nevada.","length":545,"tagName":"p"},{"type":"text","content":"Robert R. Redfield, MD, Chief Medical Officer for Traws Pharma and former Director of the U.S. Centers for Disease Control and Prevention (CDC), commented, “Traws designed ratutrelvir to overcome the limitations of current COVID treatments. COVID continues to be a significant cause of mortality for older adults with underlying medical conditions and people who are immunocompromised1. Requirement to use the boosting agent ritonavir with widely used treatment2 increases drug-drug interaction risk for patients with complex medical conditions and may limit patient eligibility for therapy3. Data ...